| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | 28.99% | 27.38% | 31.32% | 32.51% | 31.45% | 29.33% |
| Operating Margin | 16.76% | 14.60% | 18.49% | 19.56% | 19.22% | 15.57% |
| EBITDA Margin | 24.22% | 21.90% | 25.72% | 26.15% | 25.90% | 23.75% |
| Net Margin | 11.79% | 10.67% | 13.42% | 14.54% | 15.91% | 11.87% |
| Current Ratio | — | — | — | — | — | — |
| Quick Ratio | — | — | — | — | — | — |
| Debt / Equity | 0.23 | 0.23 | 0.23 | 0.15 | 0.24 | 0.95 |
| ROE | 9.41% | 8.39% | 12.86% | 14.36% | 15.95% | 25.34% |
| ROA | 5.50% | 5.06% | 7.03% | 8.62% | 9.46% | 8.12% |
| Asset Turnover | 0.47 | 0.47 | 0.52 | 0.59 | 0.59 | 0.68 |
| Book Value / Share | 5.45 | 5.18 | 4.61 | 3.94 | 3.49 | 1.10 |
Stevanato Group S.p.A. is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The company offers an integrated portfolio of products, processes, and services that support customers across the entire drug life cycle, from development and clinical stages to commercial production. Its Biopharmaceutical and Diagnostic Solutions segment provides glass primary packaging such as vials, cartridges, syringes, and ampoules, alongside plastic components for drug delivery systems and in-vitro diagnostic consumables. The Engineering segment delivers specialized equipment including visual inspection systems, assembly lines, glass converting machinery, secondary packaging solutions, and analytical services to ensure product quality and regulatory compliance. Stevanato Group S.p.A. emphasizes technological innovation, manufacturing excellence, and a global footprint with production sites in multiple countries. Founded in 1949 and headquartered in Piombino Dese, Padua, Italy, it serves major players in the biopharmaceutical sector with end-to-end solutions for injectable drugs and diagnostic applications.